Home LiteratureArticle Details
PMID: 20457567 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Involvement of members of the cadherin superfamily in cancer.

Cold Spring Harbor perspectives in biology ·Vol. 1 ·No. 6 ·2009-12-00 ·Pages a003129

Berx G, van Roy F

Abstract

We review the role of cadherins and cadherin-related proteins in human cancer. Cellular and animal models for human cancer are also dealt with whenever appropriate. E-cadherin is the prototype of the large cadherin superfamily and is renowned for its potent malignancy suppressing activity. Different mechanisms for inactivating E-cadherin/CDH1 have been identified in human cancers: inherited and somatic mutations, aberrant protein processing, increased promoter methylation, and induction of transcriptional repressors such as Snail and ZEB family members. The latter induce epithelial mesenchymal transition, which is also associated with induction of "mesenchymal" cadherins, a hallmark of tumor progression. VE-cadherin/CDH5 plays a role in tumor-associated angiogenesis. The atypical T-cadherin/CDH13 is often silenced in cancer cells but up-regulated in tumor vasculature. The review also covers the status of protocadherins and several other cadherin-related molecules in human cancer. Perspectives for emerging cadherin-related anticancer therapies are given.

MeSH Terms
Cadherins/genetics,metabolism Gene Expression Regulation, Neoplastic/physiology Humans Multigene Family Mutation Neoplasms/metabolism
Chemicals
Cadherins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Berx Geert
Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium.
van Roy Frans
References (213)
213 references, click to expand
  1. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.
    Int J Oncol. 2004 Sep;25(3):685-91 PMID: 15289870
  2. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.
    Oncogene. 2002 Nov 7;21(51):7861-71 PMID: 12420223
  3. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
    Cancer Cell. 2006 Nov;10(5):437-49 PMID: 17097565
  4. Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma.
    Lab Invest. 2002 Aug;82(8):1023-9 PMID: 12177241
  5. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule.
    Mol Cell Endocrinol. 2003 Apr 28;202(1-2):89-96 PMID: 12770736
  6. Mutations of the E-cadherin gene in human gynecologic cancers.
    Nat Genet. 1994 May;7(1):98-102 PMID: 8075649
  7. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.
    Oncogene. 2005 Mar 31;24(14):2375-85 PMID: 15674322
  8. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.
    Genes Dev. 2006 Mar 1;20(5):543-56 PMID: 16481467
  9. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  10. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network.
    Nat Rev Cancer. 2007 Mar;7(3):182-91 PMID: 17318211
  11. Cadherin-11 is expressed in invasive breast cancer cell lines.
    Cancer Res. 1999 Feb 15;59(4):947-52 PMID: 10029089
  12. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail.
    Mol Cell Biol. 2007 Jan;27(1):157-69 PMID: 17060462
  13. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas.
    Oncogene. 2002 May 9;21(20):3241-6 PMID: 12082640
  14. Identification of 20 genes aberrantly methylated in human breast cancers.
    Int J Cancer. 2005 Sep 1;116(3):407-14 PMID: 15818620
  15. Characterization of microRNA expression profiles in normal human tissues.
    BMC Genomics. 2007 Jun 12;8:166 PMID: 17565689
  16. Activity-induced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases.
    Neuron. 2007 Nov 8;56(3):456-71 PMID: 17988630
  17. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Cancer Res. 2006 Mar 1;66(5):2725-31 PMID: 16510593
  18. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
    Clin Cancer Res. 2001 Oct;7(10):3289-97 PMID: 11595727
  19. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.
    Cancer Res. 2004 May 1;64(9):3103-11 PMID: 15126347
  20. A causal role for E-cadherin in the transition from adenoma to carcinoma.
    Nature. 1998 Mar 12;392(6672):190-3 PMID: 9515965
  21. P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma.
    Cancer Res. 2005 Oct 1;65(19):8774-83 PMID: 16204047
  22. E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion.
    Cancer Res. 2006 Oct 15;66(20):10007-15 PMID: 17047063
  23. Mutations of the human E-cadherin (CDH1) gene.
    Hum Mutat. 1998;12(4):226-37 PMID: 9744472
  24. Hereditary diffuse gastric cancer.
    Adv Cancer Res. 2001;83:55-65 PMID: 11665720
  25. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    Nat Rev Cancer. 2007 Jun;7(6):415-28 PMID: 17508028
  26. E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.
    Am J Pathol. 2001 Dec;159(6):2117-24 PMID: 11733362
  27. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.
    J Clin Oncol. 2003 Apr 15;21(8):1472-9 PMID: 12697869
  28. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
    Int J Cancer. 2008 Jan 1;122(1):71-7 PMID: 17721921
  29. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.
    J Biol Chem. 2000 Jan 28;275(4):2727-32 PMID: 10644736
  30. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions.
    Nucleic Acids Res. 2005 Nov 24;33(20):6566-78 PMID: 16314317
  31. Endothelial cell-cell junctions: happy together.
    Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70 PMID: 15071551
  32. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone.
    Int J Oncol. 2008 Jul;33(1):17-24 PMID: 18575746
  33. Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus.
    J Virol. 2008 Oct;82(19):9615-28 PMID: 18667499
  34. Germline E-cadherin mutations in familial lobular breast cancer.
    J Med Genet. 2007 Nov;44(11):726-31 PMID: 17660459
  35. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation.
    Cancer Res. 2007 Apr 1;67(7):3106-16 PMID: 17409417
  36. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer.
    Clin Exp Metastasis. 2007;24(8):587-97 PMID: 17978854
  37. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis.
    Cancer Lett. 2000 Jan 1;148(1):73-80 PMID: 10680595
  38. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
    Cancer Res. 2001 Dec 15;61(24):8659-63 PMID: 11751381
  39. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions.
    EMBO J. 2005 Mar 23;24(6):1146-56 PMID: 15775979
  40. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region.
    Int J Cancer. 2002 Nov 20;102(3):225-9 PMID: 12397640
  41. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.
    Oncogene. 1996 Nov 7;13(9):1919-25 PMID: 8934538
  42. N-cadherin as a therapeutic target in cancer.
    Expert Opin Investig Drugs. 2007 Apr;16(4):451-65 PMID: 17371194
  43. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
    Cancer Res. 2008 Feb 15;68(4):989-97 PMID: 18281472
  44. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Int J Cancer. 2008 Sep 1;123(5):1043-52 PMID: 18553387
  45. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1).
    Genomics. 1995 Mar 20;26(2):281-9 PMID: 7601454
  46. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.
    Cancer Res. 1994 Jul 15;54(14):3845-52 PMID: 8033105
  47. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma.
    J Pathol. 2001 Mar;193(3):310-7 PMID: 11241409
  48. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer.
    Oncogene. 2008 Aug 7;27(34):4657-65 PMID: 18408767
  49. Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
    Nat Rev Cancer. 2006 Apr;6(4):292-306 PMID: 16557281
  50. Increased expression of H/T-cadherin in tumor-penetrating blood vessels.
    Cancer Res. 2000 Sep 1;60(17):4682-8 PMID: 10987267
  51. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
    Int J Cancer. 2008 Nov 15;123(10):2331-6 PMID: 18729198
  52. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin.
    Cancer. 2007 May 1;109(9):1811-20 PMID: 17354228
  53. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.
    Br J Cancer. 2006 Mar 13;94(5):661-71 PMID: 16495925
  54. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
    Oncogene. 2001 Jun 28;20(29):3814-23 PMID: 11439345
  55. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma.
    Oncogene. 2001 Mar 22;20(12):1525-8 PMID: 11313896
  56. Prospective identification of tumorigenic breast cancer cells.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 PMID: 12629218
  57. E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus.
    Br J Cancer. 1999 Jul;80(10):1652-7 PMID: 10408414
  58. Multiple loci identified in a genome-wide association study of prostate cancer.
    Nat Genet. 2008 Mar;40(3):310-5 PMID: 18264096
  59. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.
    Int J Oncol. 1999 Oct;15(4):715-20 PMID: 10493953
  60. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions.
    Cancer Res. 2001 Feb 1;61(3):1171-7 PMID: 11221848
  61. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.
    Cell. 1991 Jul 12;66(1):107-19 PMID: 2070412
  62. Soluble cadherins as cancer biomarkers.
    Clin Exp Metastasis. 2007;24(8):685-97 PMID: 17952616
  63. Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas.
    Hum Mol Genet. 1993 Jun;2(6):803-4 PMID: 8353498
  64. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin.
    Cancer Res. 2007 Sep 1;67(17):7972-6 PMID: 17804704
  65. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
    J Cell Biol. 1991 Apr;113(1):173-85 PMID: 2007622
  66. Protocadherin-PC promotes androgen-independent prostate cancer cell growth.
    Prostate. 2006 Jul 1;66(10):1100-13 PMID: 16637074
  67. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.
    J Cell Biol. 2000 Feb 21;148(4):779-90 PMID: 10684258
  68. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    BMC Cell Biol. 2008 Jan 24;9:4 PMID: 18218096
  69. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.
    Gastroenterology. 2001 Dec;121(6):1348-53 PMID: 11729114
  70. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma.
    Clin Cancer Res. 2001 Mar;7(3):473-7 PMID: 11297236
  71. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management.
    Clin Cancer Res. 2005 Aug 1;11(15):5401-9 PMID: 16061854
  72. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
    Cancer Res. 2008 May 15;68(10):3777-84 PMID: 18483261
  73. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
    Cancer Res. 2005 Jun 15;65(12):5263-71 PMID: 15958572
  74. Recent progress in T-cadherin (CDH13, H-cadherin) research.
    Histol Histopathol. 2001 Oct;16(4):1287-93 PMID: 11642747
  75. The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression.
    Oncogene. 2008 Jun 12;27(26):3692-9 PMID: 18223680
  76. Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer.
    Cancer Sci. 2004 Jul;95(7):588-91 PMID: 15245595
  77. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis.
    Differentiation. 2007 Mar;75(3):219-34 PMID: 17288544
  78. E-cadherin germline mutations in familial gastric cancer.
    Nature. 1998 Mar 26;392(6674):402-5 PMID: 9537325
  79. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion.
    Cancer Res. 2007 Sep 1;67(17):8198-206 PMID: 17804733
  80. Paraxial protocadherin coordinates cell polarity during convergent extension via Rho A and JNK.
    EMBO J. 2004 Aug 18;23(16):3259-69 PMID: 15297873
  81. Cysteine cathepsins: multifunctional enzymes in cancer.
    Nat Rev Cancer. 2006 Oct;6(10):764-75 PMID: 16990854
  82. Use of multicellular tumor spheroids to dissect endothelial cell-tumor cell interactions: a role for T-cadherin in tumor angiogenesis.
    FEBS Lett. 2007 Sep 18;581(23):4523-8 PMID: 17765896
  83. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas.
    Neoplasia. 2005 Mar;7(3):193-9 PMID: 15799819
  84. Cancer phenomics: RET and PTEN as illustrative models.
    Nat Rev Cancer. 2007 Jan;7(1):35-45 PMID: 17167516
  85. H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo.
    Carcinogenesis. 1998 Jun;19(6):1157-9 PMID: 9667758
  86. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
    Oncogene. 2008 Nov 24;27(55):6920-9 PMID: 19029934
  87. Familial gastric cancer: overview and guidelines for management.
    J Med Genet. 1999 Dec;36(12):873-80 PMID: 10593993
  88. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression.
    J Biol Chem. 2002 Oct 18;277(42):39209-16 PMID: 12161443
  89. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness.
    Biochim Biophys Acta. 1994 May 27;1198(1):11-26 PMID: 8199193
  90. Cadherin switch in tumor progression.
    Ann N Y Acad Sci. 2004 Apr;1014:155-63 PMID: 15153430
  91. Molecular evolution of the cadherin superfamily.
    Int J Biochem Cell Biol. 2009 Feb;41(2):349-69 PMID: 18848899
  92. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor.
    Cancer Cell. 2002 Oct;2(4):301-14 PMID: 12398894
  93. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.
    Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10308-13 PMID: 15210937
  94. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.
    Cancer Res. 2008 Oct 1;68(19):7846-54 PMID: 18829540
  95. Molecular classification of cutaneous malignant melanoma by gene expression profiling.
    Nature. 2000 Aug 3;406(6795):536-40 PMID: 10952317
  96. Regional assignment of the human loci for uvomorulin (UVO) and chymotrypsinogen B (CTRB) with the help of two overlapping deletions on the long arm of chromosome 16.
    Cytogenet Cell Genet. 1989;50(2-3):145-8 PMID: 2789125
  97. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer.
    Ann Surg Oncol. 2005 Jun;12(6):488-96 PMID: 15864483
  98. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease.
    Med Mol Morphol. 2007 Sep;40(3):115-20 PMID: 17874043
  99. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14).
    Am J Physiol Renal Physiol. 2006 Jan;290(1):F43-51 PMID: 16077081
  100. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
    Clin Cancer Res. 2005 Aug 15;11(16):5869-77 PMID: 16115928
  101. E-cadherin is a survival factor for the lactating mouse mammary gland.
    Mech Dev. 2002 Jul;115(1-2):53-62 PMID: 12049767
  102. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer.
    J Clin Pathol. 2008 Jan;61(1):25-30 PMID: 17513507
  103. Separating the adhesive and signaling functions of the Fat and Dachsous protocadherins.
    Development. 2006 Jun;133(12):2315-24 PMID: 16687445
  104. The Hippo-YAP pathway: new connections between regulation of organ size and cancer.
    Curr Opin Cell Biol. 2008 Dec;20(6):638-46 PMID: 18955139
  105. Conditional targeting of E-cadherin in skin: insights into hyperproliferative and degenerative responses.
    Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):552-7 PMID: 14704278
  106. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.
    Cancer Res. 2006 May 1;66(9):4617-26 PMID: 16651412
  107. Diverse functions of p120ctn in tumors.
    Biochim Biophys Acta. 2007 Jan;1773(1):78-88 PMID: 17030444
  108. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma.
    Cell Adhes Commun. 1997 Mar;4(6):399-411 PMID: 9177902
  109. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer.
    Gastroenterology. 2006 Sep;131(3):830-40 PMID: 16952552
  110. An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways.
    Virchows Arch. 2006 Mar;448(3):311-8 PMID: 16273386
  111. P-cadherin expression in breast cancer: a review.
    Breast Cancer Res. 2007;9(5):214 PMID: 18001487
  112. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.
    EMBO Rep. 2008 Jun;9(6):582-9 PMID: 18483486
  113. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
    Am J Pathol. 1999 Sep;155(3):739-52 PMID: 10487832
  114. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.
    Genes Dev. 2008 Apr 1;22(7):894-907 PMID: 18381893
  115. Complex cadherin expression in human prostate cancer cells.
    Int J Cancer. 2000 Feb 1;85(3):446-50 PMID: 10652439
  116. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.
    Cancer Res. 2008 Jun 15;68(12):4709-18 PMID: 18559517
  117. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer.
    Hum Mol Genet. 2008 Nov 15;17(22):3566-76 PMID: 18772194
  118. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.
    J Cell Biol. 1999 Nov 1;147(3):631-44 PMID: 10545506
  119. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.
    Cancer Res. 1995 Nov 15;55(22):5195-9 PMID: 7585573
  120. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.
    EMBO J. 1995 Dec 15;14(24):6107-15 PMID: 8557030
  121. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases.
    Cancer Res. 2005 Apr 15;65(8):3092-9 PMID: 15833838
  122. Suppression of retinal neovascularization with an antagonist to vascular endothelial cadherin.
    Arch Ophthalmol. 2008 Aug;126(8):1082-8 PMID: 18695103
  123. The role of VHL in the regulation of E-cadherin: a new connection in an old pathway.
    Cell Cycle. 2007 Jan 1;6(1):56-9 PMID: 17245122
  124. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas.
    Cancer Res. 2002 Jun 15;62(12):3382-6 PMID: 12067979
  125. Cadherin switching.
    J Cell Sci. 2008 Mar 15;121(Pt 6):727-35 PMID: 18322269
  126. Methylation pattern of CDH13 gene in digestive tract cancers.
    Br J Cancer. 2004 Sep 13;91(6):1139-42 PMID: 15292927
  127. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
    Trends Biochem Sci. 1999 Feb;24(2):73-6 PMID: 10098402
  128. Atypical GPI-anchored T-cadherin stimulates angiogenesis in vitro and in vivo.
    Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2222-30 PMID: 16873731
  129. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.
    Nat Cell Biol. 2000 Feb;2(2):76-83 PMID: 10655586
  130. Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma.
    FASEB J. 2006 Nov;20(13):2291-301 PMID: 17077306
  131. E-cadherin gene alterations are rare events in thyroid tumors.
    Int J Cancer. 1997 Jan 6;70(1):32-8 PMID: 8985087
  132. H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer.
    Nat Med. 1996 Jul;2(7):776-82 PMID: 8673923
  133. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.
    J Biol Chem. 2008 Jun 27;283(26):18393-401 PMID: 18434311
  134. TGF-beta antagonists: why suppress a tumor suppressor?
    J Clin Invest. 2002 Jun;109(12):1533-6 PMID: 12070299
  135. The cell-cell adhesion molecule E-cadherin.
    Cell Mol Life Sci. 2008 Nov;65(23):3756-88 PMID: 18726070
  136. Effect of N-cadherin misexpression by the mammary epithelium in mice.
    J Cell Biochem. 2005 Aug 15;95(6):1093-107 PMID: 15838877
  137. 5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis.
    Clin Exp Metastasis. 2004;21(1):49-56 PMID: 15065602
  138. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
    Br J Haematol. 2007 Mar;136(6):829-32 PMID: 17341268
  139. Generation of breast cancer stem cells through epithelial-mesenchymal transition.
    PLoS One. 2008 Aug 06;3(8):e2888 PMID: 18682804
  140. E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia.
    Hum Mol Genet. 2006 May 15;15(10):1704-12 PMID: 16600987
  141. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability.
    Blood. 2002 Aug 1;100(3):905-11 PMID: 12130501
  142. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
    Cancer Res. 2001 Jun 1;61(11):4556-60 PMID: 11389090
  143. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.
    Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 PMID: 7543680
  144. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
    Mol Pathol. 1999 Jun;52(3):151-7 PMID: 10621837
  145. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals.
    Cancer Cell. 2008 Mar;13(3):188-92 PMID: 18328423
  146. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
    Cancer Res. 2006 Apr 1;66(7):3567-75 PMID: 16585181
  147. Glycosyl phosphatidylinositol--anchored T-cadherin mediates calcium-dependent, homophilic cell adhesion.
    J Cell Biol. 1992 Oct;119(2):451-61 PMID: 1400585
  148. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98 PMID: 16361555
  149. Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway.
    J Biol Chem. 2008 Feb 22;283(8):5127-37 PMID: 18057010
  150. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
    Gastroenterology. 2009 Feb;136(2):640-51.e1 PMID: 19084528
  151. miR-200b mediates post-transcriptional repression of ZFHX1B.
    RNA. 2007 Aug;13(8):1172-8 PMID: 17585049
  152. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis.
    Cancer Cell. 2002 May;1(4):339-53 PMID: 12086849
  153. Endothelial cadherins and tumor angiogenesis.
    Exp Cell Res. 2006 Mar 10;312(5):659-67 PMID: 16256984
  154. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.
    Blood. 2005 Jun 1;105(11):4337-44 PMID: 15701713
  155. Src, chemoresistance and epithelial to mesenchymal transition: are they related?
    Anticancer Drugs. 2007 Apr;18(4):371-5 PMID: 17351389
  156. T-cadherin, a novel cadherin cell adhesion molecule in the nervous system lacks the conserved cytoplasmic region.
    Neuron. 1991 Sep;7(3):391-402 PMID: 1654948
  157. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.
    J Cell Sci. 2001 Jan;114(Pt 1):111-118 PMID: 11112695
  158. Development of targeted angiogenic medicine.
    J Thromb Haemost. 2009 Jan;7(1):21-33 PMID: 18983480
  159. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations.
    Cell. 2003 Sep 5;114(5):635-45 PMID: 13678586
  160. delta-Protocadherins: unique structures and functions.
    Cell Mol Life Sci. 2005 Dec;62(23):2840-52 PMID: 16261259
  161. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer.
    Cancer Res. 2008 Jan 15;68(2):537-44 PMID: 18199550
  162. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.
    Reprod Sci. 2007 May;14(4):374-82 PMID: 17644810
  163. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.
    Cancer Res. 2007 Mar 1;67(5):2030-9 PMID: 17332331
  164. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.
    J Med Genet. 2004 Jul;41(7):508-17 PMID: 15235021
  165. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
    Cell. 2004 Jun 25;117(7):927-39 PMID: 15210113
  166. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
    Nat Cell Biol. 2008 May;10(5):593-601 PMID: 18376396
  167. T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression.
    Mol Cell Biol. 2003 Jan;23(2):566-78 PMID: 12509455
  168. A novel human xenograft model of inflammatory breast cancer.
    Cancer Res. 1999 Oct 15;59(20):5079-84 PMID: 10537277
  169. Characterization of cadherin-24, a novel alternatively spliced type II cadherin.
    J Biol Chem. 2003 Jul 25;278(30):27513-9 PMID: 12734196
  170. Cadherin-11 promotes the metastasis of prostate cancer cells to bone.
    Mol Cancer Res. 2008 Aug;6(8):1259-67 PMID: 18708358
  171. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.
    Nature. 2008 Nov 6;456(7218):66-72 PMID: 18987736
  172. Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation.
    Carcinogenesis. 2002 Jul;23(7):1139-48 PMID: 12117771
  173. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.
    Cancer Res. 1998 May 15;58(10):2063-6 PMID: 9605742
  174. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
    Int J Oncol. 2008 May;32(5):1057-63 PMID: 18425332
  175. Identification of proteins associating with glycosylphosphatidylinositol- anchored T-cadherin on the surface of vascular endothelial cells: role for Grp78/BiP in T-cadherin-dependent cell survival.
    Mol Cell Biol. 2008 Jun;28(12):4004-17 PMID: 18411300
  176. Downregulation of expression of a novel cadherin molecule, T-cadherin, in basal cell carcinoma of the skin.
    Mol Carcinog. 2002 Dec;35(4):173-9 PMID: 12489108
  177. T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells.
    J Invest Dermatol. 2005 Apr;124(4):833-8 PMID: 15816843
  178. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
    Oncogene. 2002 Jul 11;21(30):4646-62 PMID: 12096341
  179. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers.
    Int J Cancer. 2009 Feb 15;124(4):793-8 PMID: 19048595
  180. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Cancer. 2005 Nov 1;104(9):1825-33 PMID: 16177988
  181. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Am J Pathol. 1996 Dec;149(6):2089-94 PMID: 8952541
  182. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.
    Nucleic Acids Res. 2002 Nov 1;30(21):4770-80 PMID: 12409468
  183. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.
    J Biol Chem. 2008 May 30;283(22):14910-4 PMID: 18411277
  184. Persistent E-cadherin expression in inflammatory breast cancer.
    Mod Pathol. 2001 May;14(5):458-64 PMID: 11353057
  185. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
    Cancer. 2002 Jan 15;94(2):386-92 PMID: 11900224
  186. Epigenetic versus genetic alterations in the inactivation of E-cadherin.
    Semin Cancer Biol. 2002 Oct;12(5):373-9 PMID: 12191636
  187. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.
    Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23 PMID: 11416160
  188. Insights into the low adhesive capacity of human T-cadherin from the NMR structure of Its N-terminal extracellular domain.
    J Biol Chem. 2008 Aug 22;283(34):23485-95 PMID: 18550521
  189. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.
    Cancer Res. 2008 Dec 1;68(23):9918-27 PMID: 19047173
  190. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells.
    Cancer Res. 2004 Nov 15;64(22):8309-17 PMID: 15548699
  191. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site.
    J Biol Chem. 2001 Sep 21;276(38):35808-17 PMID: 11445581
  192. Cadherin switching in human prostate cancer progression.
    Cancer Res. 2000 Jul 1;60(13):3650-4 PMID: 10910081
  193. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.
    Am J Pathol. 2002 Nov;161(5):1881-91 PMID: 12414534
  194. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease.
    Nat Genet. 2008 Aug;40(8):1010-5 PMID: 18604206
  195. The transcriptional repressor Snail promotes mammary tumor recurrence.
    Cancer Cell. 2005 Sep;8(3):197-209 PMID: 16169465
  196. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.
    Cancer Res. 2004 Nov 15;64(22):8156-9 PMID: 15548679
  197. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast.
    Int J Cancer. 2001 May 1;92(3):404-8 PMID: 11291078
  198. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.
    Nat Genet. 2000 Sep;26(1):16-7 PMID: 10973239
  199. DNA methylation markers and early recurrence in stage I lung cancer.
    N Engl J Med. 2008 Mar 13;358(11):1118-28 PMID: 18337602
  200. The H-cadherin (CDH13) gene is inactivated in human lung cancer.
    Hum Genet. 1998 Jul;103(1):96-101 PMID: 9737784
  201. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
    Cancer Res. 2000 Aug 15;60(16):4346-8 PMID: 10969774
  202. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex.
    Nat Cell Biol. 2002 Mar;4(3):222-31 PMID: 11836526
  203. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  204. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.
    Oncogene. 2006 Feb 16;25(7):1070-80 PMID: 16247458
  205. delta-Protocadherins: a gene family expressed differentially in the mouse brain.
    Cell Mol Life Sci. 2005 Jun;62(11):1247-59 PMID: 15905963
  206. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model.
    Cancer Res. 2008 Mar 1;68(5):1407-16 PMID: 18316604
  207. Genetics, pathology, and clinics of familial gastric cancer.
    Int J Surg Pathol. 2006 Jan;14(1):21-33 PMID: 16501831
  208. Molecular alterations of E-cadherin gene: possible role in human bladder carcinogenesis.
    Int J Mol Med. 2000 Aug;6(2):201-8 PMID: 10891567
  209. Cell adhesion and drug resistance in cancer.
    Curr Opin Oncol. 1997 Nov;9(6):549-56 PMID: 9370076
  210. Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain.
    Mamm Genome. 2000 Oct;11(10):906-14 PMID: 11003707
  211. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells.
    J Cell Biol. 1997 Dec 29;139(7):1861-72 PMID: 9412478
  212. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Cancer. 2005 Apr 15;103(8):1631-43 PMID: 15742334
  213. Ovarian cancer metastasis: integrating insights from disparate model organisms.
    Nat Rev Cancer. 2005 May;5(5):355-66 PMID: 15864277
Article Info
Journal
Cold Spring Harbor perspectives in biology
Abbr.
Cold Spring Harb Perspect Biol
ISSN
1943-0264
DOI
10.1101/cshperspect.a003129
Published
2009-12-00
Epub
2009-00-23
Pages
a003129
Language
English
Region
United States
NLM ID
101513680
PMCID
PMC2882122
Subset
IM
Grants
Worldwide Cancer Research · 06-0570 · United Kingdom
External Links
PubMed source DOI: 10.1101/cshperspect.a003129 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2